宁泌泰胶囊辅助治疗女性膀胱过度活动症132例报告

目的:观察宁泌泰胶囊辅助治疗女性膀胱过度活动症(Overactive bladder,OAB)的治疗效果.方法:将132例女性OAB患者随机分为实验组和对照组.实验组66例,用M受体拮抗剂,同时加用宁泌泰胶囊;对照组66例,单用M受体拮抗剂,两组疗程均为2周.结果:实验组的临床治愈率为45.45%,总有效率为93.93%;对照组的临床治愈率为30.33%,总有效率为90.91%,两组比较差异有统计学意义(P＜0.05).结论:宁泌泰胶囊辅助治疗女性膀胱过度活动症是有效的.     

索利那新联合盐酸坦洛新治疗经尿道前列腺剜除术后膀胱过度活动症的临床研究

目的探讨索利那新联合盐酸坦洛新治疗经尿道等离子解剖性前列腺剜除术(transurethral anatomical enucleation of prostate,TUAERP)后膀胱过度活动症状(overactive bladder,OAB)的疗效。方法选取2015年10月至2017年10月在潍坊市中医院接受TUAERP治疗的良性前列腺增生(benign prostatic hyperplasia,BPH)患者共90例,随机分为3组,每组30例。三组患者术后分别接受索利那新联合盐酸坦洛新(A组)、盐酸坦洛新(B组)及吲哚美辛栓(C组)治疗出现的OAB症状,比较各组术后72小时内膀胱痉挛等症状的发生次数和持续时间、拔除尿管后1周的排尿情况以及药物不良反应。结果术后72小时内A组、B组发生OAB次数和平均持续时间均少于C组(P0.01),A组发生OAB次数和平均持续时间均少于B组(P0.05);拔除尿管后1周,A组、B组及C组的国际前列腺症状评分(international prostate symptom score,IPSS)和生活质量评分(quality of life score,Qo L)较术前均有明显下降,差异有统计学意义(P0.05);相比于C组,A组和B组的膀胱过度活动症状评分(overactive bladder symptom score,OABSS)明显降低(P0.01),但两者之间差异无统计学意义(P0.05)。结论经尿道等离子前列腺剜除术后早期联合使用索利那新和盐酸坦洛新可以安全有效地缓解OAB的发生,有利于患者术后的恢复。     

伴前列腺炎的不育症患者治疗后的精液分析

目的分析并比较单纯用药、单纯理疗、药物联合前列腺理疗这3种方法对伴前列腺炎不育症患者治疗的效果。方法从06年7月至07年7月间，对60例伴前列腺炎不育患者中的少弱精子症人群随机分为3组（A、B、C）。A组（20例）采用葡萄糖酸锌颗粒70mg口服3次，d，天然维生素E胶丸100mg口服，1次／d；维生素C片100mg口服，1次/d，复方玄驹胶囊1．26g口服，3次/d，胰激肽释放酶120u口服，3次，d及服用敏感抗生素2周（如复方新诺明或左氧氟沙星等）。B组（20例）单纯行前列腺物理治疗，即用前列腺治疗仪治疗，3次，周，且治疗后每晚坐浴1次，l5min／次（水温37℃-42℃）。C组（20例）是A组与B组的联合治疗。结果3组治疗前与治疗后检查分析精液，示治疗后精液质量均改善，但C组精液各项参数明显较A、B组要高，差异有显著意义（P〈0．01）。结论对伴前列腺炎不育症患者行药物治疗联合前列腺物理治疗后，患者精液质量明显改善；且明显优于单纯药物治疗或单纯理疗。     

索利那新治疗前列腺电切术后膀胱过度活动症的临床观察

目的比较索利那新及托特罗定治疗经尿道前列腺电切术（TURP）术后患者膀胱过度活动症（OAB）的有效性与安全性。方法选取126例TURP后出现OAB症状的患者,随机分为4组：A组（索利那新5mg,1次/d）,B组（索利那新10mg,1次/d）,C组（托特罗定2mg,2次/d）,D组（安慰剂组）。术后6h开始服药,观察治疗前及拔管后7d日间排尿次数、夜间排尿次数、尿急、急迫性尿失禁以及对日常生活造成的影响。进一步进行OAB症状评分表（OABSS）评分和感知膀胱症状量表（PPBC）评分;观察各组口干、便秘、视力模糊症状等不良反应的发生率以及肝功能、肾功能指标变化。结果拔管后7d,A、B、C组与D组OABSS及PPBC评分有显著性差异（P〈0.05）,A、B组,B、C组,A、C组之间无显著性差异（P〉0.05）。A组2例出现口干,1例便秘;B组5例口干,3例便秘,2例视力模糊;C组有4例口干,2例便秘,1例视力模糊;D组仅1例便秘。各组第7d复查的肝功能、肾功能与术前相比无统计学差异（P〉0.05）。结论索利那新治疗TURP术后OAB症状比托特罗定更安全,5mg足以发挥疗效,副作用更少。     

托特罗定联合硝苯地平治疗女性膀胱过度活动症的疗效观察

目的探讨托特罗定联合硝苯地平治疗女性膀胱过度活动症（OAB）的疗效。方珐女性OAB患者60例,随机分为2组：A组（30例,托特罗定片2mg,2次／d,连服4周）,B组（30例,托特罗定片并硝苯地平片,5mg,3次／d,连用4周）。治疗前及结束后行ABSS评分。结果A组患者治疗前后尿急评分分别为（3．6±1．O）与（1．8±O．5）分,OABSS评分分别为（10．9±4．8）与（5．3±1．8）分;B组患者治疗前后尿急评分分别为（3．7±0．9）与（O．8±0．1）分,OABSS评分分别为（10．8±1．8）与（3．8±1．7）分,2组治疗前后差异均有统计学意义（P〈0．05）,2组治疗后尿急评分和OABSS评分差异有统计学意义（P〈0．05）。结论托特罗定联合硝苯地平治疗女性膀胱过度活动症效果较好。     

光子治疗仪联合金马洗剂治疗混合痔术后水肿

目的:观察光子治疗仪联合金马洗剂治疗混合痔术后并发创面水肿的疗效。方法:将160例混合痔术后患者随机分为对照组(A组)、光子治疗组(B组)、金马洗剂组(C组)及光子治疗联合金马洗剂组(D组),治疗组分别予以相应治疗,对照组常规治疗,5 d为1疗程,两个疗程后判断疗效并进行统计分析。结果:A组有效率为80.0%,B组有效率为90.0%、C组为95.0%、D组为97.5%,各治疗组有效率明显优于A组(P0.05)。各组治疗前症状积分比较差异无统计学意义(P0.05),治疗后D组症状积分明显优于B、C组,且各治疗组治疗后症状积分均优于A组。结论:光子治疗仪联合金马洗剂能明显促进痔术后水肿吸收消散,优于单纯光子治疗仪照射和金马洗剂坐浴。     

针灸联合M受体拮抗剂治疗膀胱过度活动症患者的护理

目的观察针灸疗法联合M受体拮抗剂治疗膀胱过度活动症的临床治疗护理效果。方法对273例膀胱过度活动症患者运用固定穴位针灸联合M受体拮抗剂进行治疗,采取心理、行为、膀胱功能训练等护理措施。结果患者24h排尿次数、夜尿次数明显减少,最大尿流率增加。结论心理、行为、膀胱功能训练等护理措施是针灸联合M受体拮抗剂治疗膀胱过度活动症患者护理的关键。     

射频靶点热凝联合连续硬膜外注射治疗腰椎间盘突出症

目的研究分析数字血管减影引导下射频靶点热凝联合连续患者自控硬膜外注射治疗腰椎间盘突出症的临床疗效。方法 2010年5月至2011年12月间收治的240例腰椎间盘突出症患者,分成三组:单纯射频靶点热凝术治疗组(A组,n=90),射频靶点热凝术联合单次硬膜外腔神经阻滞治疗组(B组,n=77),射频靶点热凝联合连续患者自控硬膜外腔神经阻滞治疗组(C组,n=73)。治疗效果采用改良的MacNab标准进行评定。结果术后3 d及术后3个月,B、C组的优良率均高于A组,有显著性差异;C组术后3 d优良率高于B组,有显著性差异;术后3个月,B、C组优良率无显著性差异。结论联合治疗效果比单一射频治疗疗效更好。联合治疗缓解疼痛比单纯射频更快,术后即刻见效,而采用PECA比单次硬膜外注射早期疗效更加平稳,但是长期疗效并无明显差别。     

脑源性神经营养因子在膀胱过度活动症无创诊断中的应用研究

目的:探讨脑源性神经营养因子(BDNF)在膀胱过度活动症(OAB)患者尿液中的表达及与OAB严重程度的相关性,了解BDNF在OAB无创诊断中的意义和应用价值。方法:2012年5月~2014年10月我院收治53例OAB患者(A组),年龄18~78岁,平均(47.000±16.282)岁,其中男12例,女41例。同期选择49例无OAB相关症状且膀胱过度活动症症状评分表(OABSS)正常的健康体检者作为正常对照组(B组)。两组患者均用酶联免疫吸附法(ELISA)检测尿液中BDNF含量。A组给予口服索利那新治疗,持续用药4周后再次填写OABSS、检测尿液中BDNF含量。比较A、B两组尿液中BDNF含量、OABSS评分差异及A组用药前后尿液中BDNF含量、OABSS评分差异。每个检测样本尿液中BDNF含量值除以该样本尿肌酐值(Cr)进行标准化。结果:A组与B组BDNF/Cr分别为(1.077±0.634)和(0.454±0.231),OABSS分别为(8.660±2.449)和(0.469±0.680),两组比较差异有统计学意义(P=0.000)。A组治疗前后尿液中BDNF/Cr分别为(1.077±0.634)和(0.559±0.290),OABSS评分分别为(8.660±2.449)和(3.264±1.483),前后比较差异有统计学意义(P=0.000)。A组尿液中BDNF/Cr与OAB严重程度呈显著的相关关系(r=0.729,P=0.000)。结论:OAB患者尿液中BDNF含量明显升高,且与OAB的严重程度显著相关。经过索利那新治疗后病情缓解的OAB患者尿液中BDNF含量明显降低。BDNF可作为OAB无创诊断和疗效判定的客观指标。     

不同中药坐浴方法联合康复新液湿敷对痔术后创面疼痛和愈合的影响

目的观察不同中药坐浴方法联合康复新液湿敷对痔术后创面疼痛和愈合的影响。方法选取200例住院手术治疗的混合痔患者,分为A、B、C、D四个组,每组各50例。A组采取便后中药坐浴,B组采取便前与便后中药坐浴,C组便后中药坐浴联合康复新液湿敷,D组便前与便后中药坐浴联合康复新液湿敷。比较四组创面愈合时间、创面疼痛(采用视觉模拟评分法VAS评估)、创面出血、创面水肿及创面肉芽生长情况。结果 C组与D组创面愈合时间分别为(8.85±1.62)d和(8.63±1.74)d,明显短于A组与B组的(11.32±2.00)d和(11.01±1.95)d(均P0.05)。四组术后第3 d、第7 d的VAS疼痛评分均低于术后第1 d(均P0.05)。C组与D组的术后第7 d的VAS疼痛评分低于A组与B组(均P0.05),D组术后第7 d的VAS疼痛评分低于C组(P0.05)。C组与D组术后第7 d的创面出血、创面水肿情况均轻于A组与B组(均P0.05),创面肉芽生长情况优于A组与B组(均P0.05)。结论中药坐浴联合康复新液湿敷可减轻术后疼痛,减少痔术后创面伤口水肿、出血发生及促进肉芽生长,有利于创面加速愈合,便前及便后坐浴可进一步减轻疼痛。     

索利那新加坦索罗辛治疗膀胱过度活动症的疗效分析

目的 探讨索利那新加坦索罗辛治疗膀胱过度活动症(OAB)的疗效.方法 OAB患者53例,男15例,女38例.年龄29～72岁,平均43岁.随机分为2组,A组为单用索利那新组(27例),B组为索利那新加用坦索罗辛组(26例).服药方法:索利那新5 mg/d,坦索罗辛0.2 mg/d.连续14 d后随访,再进行OABSS评分.结果 A组患者治疗前后尿急评分分别为(3.3±1.0)与(1.9±0.6)分,OABSS评分分别为(10.8±4.9)与(5.2±1.8)分;B组患者治疗前后尿急评分分别为(3.6±1.0)与(0.9±0.1)分,OABSS评分分别为(10.7±1.9)与(3.9±1.8)分,2组治疗前后差异均有统计学意义(P＜0.05),2组治疗后尿急评分和OABSS评分差异有统计学意义(P＜0.05).结论 索利那新加用坦索罗辛可以有效缓解OAB患者的尿急症状并降低OABSS评分,索利那新加用坦索罗辛疗效好于单用索利那新.

Abstract：

Objective To evaluate the efficacy of solifenacin with or without tamsulosin in patients with overactive bladder (OAB).Methods Fifty-three patients with OAB were randomly divided into two groups (group A 27 patients, group B 26 patients).The patients received either solifenacin 5 mg/day in group A or combined with Tamsulosin 0.2 mg/day in group B for two weeks.During the treatent period all the patients recorded voiding and adverse events in a diary.The symptoms of urgency, frequency, incontinence were evaluated by OABSS scores at the begining and end of the therapy period.The results of the efficacy and safety were analyzed by using SPSS 13.0.Results The OABSS scores at the begining and end for the two groups were significantly different ( P ＜ 0.01 ).In both groups the efficacy was obvious.The OABSS scores at the end of the therapy between group A and B were significantly different (P ＜0.05 ).The efficacy of group B was better than that of group A.Conclusion The efficacy of solifenacin combined with tamsulosin was better than solifenacin alone in OAB.     

Behavioral therapies for overactive bladder: making sense of the evidence.

Overactive bladder (OAB) is a symptom-based syndrome characterized by the presence of urgency, which is defined as a sudden and compelling desire to void that cannot be postponed. OAB may significantly impact of quality of life. Numerous treatment options exist for OAB, including behavioral therapies such as pelvic floor muscle rehabilitation, bladder training, and dietary modification, as well as traditional therapies such as pharmacological therapy and neuromodulation. Behavioral therapies are considered the mainstay of treatment for urinary incontinence in general. However the efficacy of these noninvasive strategies for OAB treatment has not been well addressed in the literature. This article presents an overview of current evidence with attention to the clinical relevance of findings related to lifestyle modification, bladder training, and pelvic floor muscle training. Initial evidence suggests that obesity, smoking, and consumption of carbonated drinks are risk factors for OAB but there is less support for the contributory role of caffeine or the impact of caffeine reduction. The evidence supporting bladder training and pelvic floor muscle training is more consistent and a trend towards combining these therapies to treat OAB appears positive. Given the prevalence of OAB and growing support for the efficacy of behavioral treatments it is important and timely to augment existing evidence with well-designed multicenter trials.     

Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible‐dose regimen: results from a randomized study

Study Type – Therapy (RCT)
Level of Evidence 1b

OBJECTIVE

To compare the efficacy of flexible‐dose solifenacin 5/10 mg with and without simplified bladder training in patients with overactive bladder (OAB) syndrome.

PATIENTS AND METHODS

SOLAR (SOLifenacin Alone and with simplified bladder Re‐training) was a multicentre, prospective, randomized, parallel‐group, open‐label study in patients with OAB. After a 2‐week, single‐blind, placebo run‐in, 643 patients were randomized to treatment with either solifenacin 5 mg once daily (od) alone (323) or 5 mg od combined with simplified bladder training (320) for 8 weeks. At week 8, patients in both groups could request a dose increase to solifenacin 10 mg od for the remaining 8 weeks of the study. The primary efficacy endpoint was the change from baseline in the mean number of micturitions/24 h after 8 weeks. Secondary efficacy measures were the change in micturition frequency and other voiding diary variables at week 16. Patient‐reported outcomes were also assessed, including patient Perception of Bladder Condition, Incontinence Quality of Life, and Treatment Satisfaction using a visual analogue scale score; tolerability was also assessed.

RESULTS

Solifenacin given alone was effective in improving all measures of OAB evaluated in the study. When simplified bladder training was used combined with solifenacin there was a further significant improvement in micturition frequency at week 8, and this difference was maintained through to week 16. The use of simplified bladder training with solifenacin also significantly improved treatment satisfaction at week 16 over the responses to solifenacin given alone. There was no significant difference between the treatment groups at week 16 in urgency, incontinence or other secondary variables measured. The most common adverse event reported was dry mouth in both treatment groups; there was a low rate of discontinuation due to adverse events in the total study group.

CONCLUSION

Combined treatment with solifenacin and simplified bladder training was more effective than solifenacin alone in reducing micturition frequency at weeks 8 and 16, and improving treatment satisfaction at week 16 in patients with OAB. Simplified bladder training did not improve on the benefits of solifenacin alone in the symptoms of urgency or incontinence.     

索利那新治疗膀胱过度活动症的有效性及安全性分析

目的 评价索利那新治疗膀胱过度活动症(OAB)的有效性及安全性. 方法采用多中心临床试验方法,对216例OAB患者予每日口服5 mg索利那新,连续用药5周,记录用药前后排尿日记及用药不良反应,比较用药前后平均24 h尿急次数、平均24 h排尿次数、夜尿次数、平均尿量、尿失禁次数及QOL评分的改善情况.采用SPSS 13.0统计软件对疗效和安全性进行分析. 结果 216例患者应用索利那新治疗5周,治愈187例(86.7%),其中43例(19.9%)用药3周后基本恢复正常排尿,29例(13.4%)明显好转,24 h平均尿急次数中位数由用药前的4.1(0.9～18.6)次减至用药后的0.6(0～17.9)次,其中27例急迫性尿失禁患者24 h尿失禁次数中位数由用药前的1.9(0.6～16.4)次减至用药后的0.5(0～3.4)次,QOL评分由用药前的4.3±0.3降至用药后的1.1±0.2,用药前后比较差异均有统计学意义(P<0.05).11例(5.0%)用药后发生轻微口干、眼干症状,未观察到严重不良反应. 结论 索利那新能有效改善OAB患者尿急、尿频、夜尿及尿失禁症状,不良反应小,治疗OAB安全有效.     

阴道锥体训练联合生物反馈盆底肌治疗尿失禁老年人盆底肌康复研究现状

目的研究阴道锥体训练联合生物反馈盆底肌治疗尿失禁老年人的临床疗效及对盆底肌的影响。方法选取84例从2016年9月至2018年3月本院收治的尿失禁老年患者进行研究,以随机抽签法将其均分为联合组及对照组,每组42例。对照组予以常规盆底肌训练治疗,联合组则予以阴道锥体训练联合生物反馈盆底肌治疗。对比两组在临床疗效、治疗前后盆底肌力情况、治疗前后尿动力学参数指标水平以及生活质量变化情况等方面的差异。结果联合组与对照组在总有效率方面比较,前者高于后者(P<0.05)。治疗后联合组盆底肌力分级为Ⅳ级、Ⅴ级的人数占比相比对照组较高(P<0.05)。治疗后联合组与对照组在VLPP、PMUC水平方面比较,前者高于后者(P<0.05)。治疗后联合组与对照组I-QOL评分相比治疗前较高,且联合组相比对照组较高(P<0.05)。结论阴道锥体训练联合生物反馈盆底肌治疗老年尿失禁患者的疗效显著,有利于促进盆底肌力的恢复,且有效改善患者尿动力学参数,提高生活质量,具有较高的临床推广应用价值。     

针刺联合生物反馈治疗女性产后盆底失弛缓综合征

为探讨针刺联合生物反馈治疗女性产后盆底失弛缓综合征的疗效,选取产后42d的产妇进行盆底肌电图及肛管压力测定,评估其盆底功能,将临床便秘症状明显的40例产后盆底失弛缓综合征患者作为观察对象,随机分为治疗组和对照组各20例。对照组患者自己进行提肛锻炼,治疗组在对照组基础上应用针刺联合生物反馈治疗。比较两组在治疗前、后盆底肌力测定数据及临床症状的改善情况。结果显示,两组患者治疗后盆底肌力情况改善不明显;但肛门压力及临床症状得到明显改善,治疗组优于对照组,差异均有统计学意义（P〈0．05）。结果表明,针刺联合生物反馈治疗可有效改善女性产后盆底肛门压力及临床症状,从而提高患者的生活质量。     

Update on Behavioral and Physical Therapies for Incontinence and Overactive Bladder: The Role of Pelvic Floor Muscle Training

Behavioral and physical therapies have been used for many years to treat incontinence and overactive bladder (OAB). This paper focuses on programs that include pelvic floor muscle training (PFMT) as a component in treatment for women or men. PFMT was long used almost exclusively for treatment of stress incontinence. When it became evident that voluntary pelvic floor muscle contraction can be used to control bladder function, PFMT was also integrated into the treatment of urge incontinence and OAB as part of a broader behavioral urge suppression strategy. PFMT has evolved over decades, both as a behavioral therapy and a physical therapy, combining principles from behavioral science, nursing, and muscle physiology into a widely recommended conservative treatment. The collective literature indicates that PFMT is effective for incontinence, as well as urgency, frequency, and nocturia. It can be combined with all other treatment modalities and holds potential for prevention of bladder symptoms.     

生物反馈电刺激联合药物在绝经后盆腔器官脱垂盆底重建术后应用

目的探究生物反馈电刺激技术联合雌二醇凝胶用于绝经后盆腔器官脱垂（POP）患者盆底重建术后的疗效及其对并发症的影响。 方法选取2019年10月至2021年10月秦皇岛市第一医院妇科病区及妇科门诊收治的绝经后POP行盆底重建术的患者222例为研究对象,将符合入组标准的患者按随机数字表法分成3组：生物反馈电刺激组（A组）、药物疗法组（B组）、生物反馈电刺激联合药物疗法组（C组）。每组各74例患者。观察3组患者盆底肌力、盆底肌电活动评分、尿动力学、并发症及生活质量。 结果干预后C组盆底肌力等级较A、B组显著升高（P<0.05）,A、B组比较差异无统计学意义（P=0.952）;干预后3组盆底肌电活动评分及生活质量（SF-36）评分均升高,C组指标均优于A、B组（P<0.05）,A、B组比较差异均无统计学意义（P=0.118,P=0.881）;干预后3组尿动力学指标均升高,且C组指标均显著高于A、B组（P<0.05）,A、B组比较差异均无统计学意义（P=0.621,P=0.668,P=0.306）;干预后C组并发症总发生率明显低于A、B组（P<0.05）。 结论生物反馈电刺激技术联合雌二醇凝胶用于绝经后POP患者盆底重建术后疗效显著,可降低并发症发生率。     

Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg

OBJECTIVE: To compare OAB symptom outcomes following initial randomised treatment with solifenacin 5 mg or tolterodine ER 4 mg at the 4-week clinic-visit and again at 12 weeks for patients choosing to remain on this treatment dose from 4 weeks. METHODS: A prospective, double blind, double-dummy, two-arm, parallel-group, 12-week study (The STAR study) was conducted to compare the efficacy and safety of solifenacin 5/10 mg and tolterodine extended release (ER) 4 mg in OAB patients. RESULTS: At 4 weeks mean improvements in OAB symptoms, including urgency, frequency (primary variable), incontinence and nocturia, were larger in patients randomised to solifenacin 5 mg; with the difference for incontinence being statistically significant (mean reduction in incontinence episodes/24 hrs in the solifenacin group of -1.30 vs. -0.90 (p=0.0181); the mean result for solifenacin 5 mg amounted to a 44% additional improvement.) There was an associated significant reduction in pad use (reduced by -1.21 vs. -0.80; p=0.0089); the mean result for solifenacin 5 mg amounted to a 51% additional improvement over that of tolterodine ER 4 mg. For patients choosing to remain on these treatments improvements in favour of solifenacin were maintained at study end (12-weeks). Treatments were well tolerated. CONCLUSIONS: Within 4 weeks solifenacin 5mg was statistically significantly better than tolterodine ER 4 mg in improving incontinence and reducing incontinence pad use. Differences in efficacy in favour of solifenacin 5 mg were maintained from 4 weeks for the duration of the study for patients choosing to remain on their starting dose.     

Structured behavioral treatment research protocol for women with mixed urinary incontinence and overactive bladder symptoms

Aims

The primary aim is to provide detailed rationale and methodology for the development and implementation of a perioperative behavioral/pelvic floor exercise research protocol for women who self‐chose surgical intervention and who may or may not have been offered behavioral treatments initially. This protocol is part of the ESTEEM trial (Effects of Surgical Treatment Enhanced with Exercise for Mixed Urinary Incontinence Trial) which was designed to determine the effect of a combined surgical and perioperative behavioral/pelvic floor exercise intervention versus surgery alone on improving mixed urinary incontinence (MUI) and overactive bladder (OAB) symptoms.

Methods

As part of a multi‐site, prospective, randomized trial of women with MUI electing midurethral sling (MUS) surgical treatment, participants were randomized to a standardized perioperative behavioral/pelvic floor exercise intervention + MUS versus MUS alone. The specific behavioral intervention included: education on voiding habits, pelvic floor muscle training (PFMT), bladder training (BT), strategies to control urgency and reduce/prevent urinary symptoms, and monitoring/promoting adherence to behavioral recommendations. To ensure consistency across all eight research sites in the pelvic floor disorders network (PFDN), selective behavioral treatments sessions were audiotaped and audited for protocol adherence.

Results

The behavioral intervention protocol includes individualization of interventions using an algorithm based on pelvic floor muscle (PFM) assessment, participant symptoms, and findings from the study visits. We present, here, the specific perioperative behavioral/pelvic floor exercise interventions administered by study interventionists.

Conclusions

This paper details a perioperative behavioral/pelvic floor exercise intervention research study protocol developed for women undergoing surgery for MUI.